NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $31.00 price target on the stock.

NRXP has been the subject of a number of other research reports. Wall Street Zen upgraded NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. Finally, BTIG Research began coverage on shares of NRx Pharmaceuticals in a research report on Wednesday, April 2nd. They set a "buy" rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, NRx Pharmaceuticals has a consensus rating of "Buy" and an average target price of $28.50.

NRx Pharmaceuticals Stock Performance

NASDAQ NRXP traded down $0.01 during trading hours on Friday, reaching $3.23. The company's stock had a trading volume of 85,539 shares, compared to its average volume of 412,755. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The stock has a market cap of $55.76 million, a PE ratio of -1.61 and a beta of 1.54. The company's 50-day moving average is $2.51 and its two-hundred day moving average is $2.45.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06. The company had revenue of $1.14 million during the quarter, compared to analysts' expectations of $1.14 million. Equities analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several hedge funds have recently modified their holdings of NRXP. Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals during the fourth quarter worth approximately $56,000. Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth $61,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth $33,000. Anson Funds Management LP raised its position in shares of NRx Pharmaceuticals by 30.3% in the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company's stock worth $408,000 after buying an additional 43,135 shares during the period. Finally, AdvisorShares Investments LLC boosted its holdings in NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock valued at $683,000 after acquiring an additional 180,229 shares during the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.